Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Non-Current Deffered Revenue: 2020-2023

Historic Non-Current Deffered Revenue for Cidara Therapeutics (CDTX) over the last 4 years, with Dec 2023 value amounting to $4.2 million.

  • Cidara Therapeutics' Non-Current Deffered Revenue fell 90.26% to $1.9 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.9 million, marking a year-over-year decrease of 90.26%. This contributed to the annual value of $4.2 million for FY2023, which is 79.32% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Non-Current Deffered Revenue of $4.2 million as of FY2023, which was down 79.32% from $20.5 million recorded in FY2022.
  • In the past 5 years, Cidara Therapeutics' Non-Current Deffered Revenue registered a high of $20.5 million during FY2022, and its lowest value of $4.2 million during FY2023.
  • In the last 3 years, Cidara Therapeutics' Non-Current Deffered Revenue had a median value of $18.4 million in 2021 and averaged $14.4 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Non-Current Deffered Revenue skyrocketed by 65.21% in 2021, and later slumped by 79.32% in 2023.
  • Over the past 4 years, Cidara Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $11.1 million in 2020, then soared by 65.21% to $18.4 million in 2021, then increased by 11.47% to $20.5 million in 2022, then slumped by 79.32% to $4.2 million in 2023.